InQuest Science Bio-Expo Live June 2026: Data, Quality, And Analytics

Visual inspection remains one of the most vulnerable points in biopharmaceutical manufacturing when critical data lives in paper files, spreadsheets, and disconnected systems. Those legacy workflows make it harder to maintain inspector qualifications, manage test kits, preserve audit trails, and use threshold study data for meaningful trend analysis—creating avoidable risk during regulatory inspections. A more resilient approach relies on purpose-built digital platforms designed for manual and automated inspection programs under cGMP expectations, including USP <790> and <1790>. By centralizing defect libraries, automating qualification schedules, and capturing reject characterization in real time, manufacturers can strengthen data integrity, shorten deviation investigations, and produce audit-ready records on demand.

Discover how a specialized digital strategy can modernize inspection oversight and support Pharma 4.0 goals.